Literature DB >> 23994138

The moyamoya disease susceptibility variant RNF213 R4810K (rs112735431) induces genomic instability by mitotic abnormality.

Toshiaki Hitomi1, Toshiyuki Habu, Hatasu Kobayashi, Hiroko Okuda, Kouji H Harada, Kenji Osafune, Daisuke Taura, Masakatsu Sone, Isao Asaka, Tomonaga Ameku, Akira Watanabe, Tomoko Kasahara, Tomomi Sudo, Fumihiko Shiota, Hirokuni Hashikata, Yasushi Takagi, Daisuke Morito, Susumu Miyamoto, Kazuwa Nakao, Akio Koizumi.   

Abstract

Moyamoya disease (MMD) is a cerebrovascular disease characterized by occlusive lesions in the Circle of Willis. The RNF213 R4810K polymorphism increases susceptibility to MMD. In the present study, we characterized phenotypes caused by overexpression of RNF213 wild type and R4810K variant in the cell cycle to investigate the mechanism of proliferation inhibition. Overexpression of RNF213 R4810K in HeLa cells inhibited cell proliferation and extended the time of mitosis 4-fold. Ablation of spindle checkpoint by depletion of mitotic arrest deficiency 2 (MAD2) did not shorten the time of mitosis. Mitotic morphology in HeLa cells revealed that MAD2 colocalized with RNF213 R4810K. Immunoprecipitation revealed an RNF213/MAD2 complex: R4810K formed a complex with MAD2 more readily than RNF213 wild-type. Desynchronized localization of MAD2 was observed more frequently during mitosis in fibroblasts from patients (n=3, 61.0 ± 8.2%) compared with wild-type subjects (n=6, 13.1 ± 7.7%; p<0.01). Aneuploidy was observed more frequently in fibroblasts (p<0.01) and induced pluripotent stem cells (iPSCs) (p<0.03) from patients than from wild-type subjects. Vascular endothelial cells differentiated from iPSCs (iPSECs) of patients and an unaffected carrier had a longer time from prometaphase to metaphase than those from controls (p<0.05). iPSECs from the patients and unaffected carrier had significantly increased mitotic failure rates compared with controls (p<0.05). Thus, RNF213 R4810K induced mitotic abnormalities and increased risk of genomic instability.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Genomic instability; MAD2; Mitotic phase; Moyamoya disease; Rs112735431; iPS cells

Mesh:

Substances:

Year:  2013        PMID: 23994138     DOI: 10.1016/j.bbrc.2013.08.067

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  20 in total

1.  RNF213 Is Associated with Intracranial Aneurysms in the French-Canadian Population.

Authors:  Sirui Zhou; Amirthagowri Ambalavanan; Daniel Rochefort; Pingxing Xie; Cynthia V Bourassa; Pascale Hince; Alexandre Dionne-Laporte; Dan Spiegelman; Ziv Gan-Or; Cathy Mirarchi; Vessela Zaharieva; Nicolas Dupré; Hatasu Kobayashi; Toshiaki Hitomi; Kouji Harada; Akio Koizumi; Lan Xiong; Patrick A Dion; Guy A Rouleau
Journal:  Am J Hum Genet       Date:  2016-10-13       Impact factor: 11.025

2.  The association between the ring finger protein 213 (RNF213) polymorphisms and moyamoya disease susceptibility: a meta-analysis based on case-control studies.

Authors:  Xun-Sha Sun; Jun Wen; Jiao-Xing Li; Rong Lai; Yu-Fang Wang; Hui-Jiao Liu; Wen-Li Sheng
Journal:  Mol Genet Genomics       Date:  2016-02-05       Impact factor: 3.291

3.  Moyamoya disease susceptibility gene RNF213 links inflammatory and angiogenic signals in endothelial cells.

Authors:  Kazuhiro Ohkubo; Yasunari Sakai; Hirosuke Inoue; Satoshi Akamine; Yoshito Ishizaki; Yuki Matsushita; Masafumi Sanefuji; Hiroyuki Torisu; Kenji Ihara; Marco Sardiello; Toshiro Hara
Journal:  Sci Rep       Date:  2015-08-17       Impact factor: 4.379

Review 4.  Research Progress of Moyamoya Disease in Children.

Authors:  Jianmin Piao; Wei Wu; Zhongxi Yang; Jinlu Yu
Journal:  Int J Med Sci       Date:  2015-07-03       Impact factor: 3.738

5.  Systematic Validation of RNF213 Coding Variants in Japanese Patients With Moyamoya Disease.

Authors:  Yosuke Moteki; Hideaki Onda; Hidetoshi Kasuya; Taku Yoneyama; Yoshikazu Okada; Kengo Hirota; Maki Mukawa; Tadashi Nariai; Shohei Mitani; Hiroyuki Akagawa
Journal:  J Am Heart Assoc       Date:  2015-05-11       Impact factor: 5.501

6.  Repeated de novo aneurysm formation after anastomotic surgery: Potential risk of genetic variant RNF213 c.14576G>A.

Authors:  Yuta Fukushima; Satoru Miyawaki; Tomohiro Inoue; Seiichiro Shimizu; Gakushi Yoshikawa; Hideaki Imai; Nobuhito Saito; Kazuo Tsutsumi
Journal:  Surg Neurol Int       Date:  2015-03-20

Review 7.  Moyamoya disease and syndromes: from genetics to clinical management.

Authors:  Stéphanie Guey; Elisabeth Tournier-Lasserve; Dominique Hervé; Manoelle Kossorotoff
Journal:  Appl Clin Genet       Date:  2015-02-16

Review 8.  Genetics and Biomarkers of Moyamoya Disease: Significance of RNF213 as a Susceptibility Gene.

Authors:  Miki Fujimura; Shinya Sonobe; Yasuo Nishijima; Kuniyasu Niizuma; Hiroyuki Sakata; Shigeo Kure; Teiji Tominaga
Journal:  J Stroke       Date:  2014-05-30       Impact factor: 6.967

Review 9.  hiPSC-derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicine.

Authors:  Vikram Sabapathy; Sanjay Kumar
Journal:  J Cell Mol Med       Date:  2016-04-21       Impact factor: 5.310

10.  Disease Variant Landscape of a Large Multiethnic Population of Moyamoya Patients by Exome Sequencing.

Authors:  Lorelei D Shoemaker; Michael J Clark; Anil Patwardhan; Gemma Chandratillake; Sarah Garcia; Rong Chen; Alexander A Morgan; Nan Leng; Scott Kirk; Richard Chen; Douglas J Cook; Michael Snyder; Gary K Steinberg
Journal:  G3 (Bethesda)       Date:  2015-11-03       Impact factor: 3.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.